FDA Delays Priority Reviews for Promising Drugs Amid Safety Concerns in New Voucher Program

Spread the Message

Read Time:3 Minute, 53 Second

The U.S. Food and Drug Administration (FDA) has delayed evaluations of two drugs under its new Commissioner’s National Priority Voucher (CNPV) program due to raised safety and efficacy issues, including a patient death linked to one treatment. Launched in June 2025 by the Trump administration, the program aims to slash standard 10-12 month review timelines to one or two months for drugs addressing national health priorities like unmet needs and domestic manufacturing. These setbacks, revealed in internal FDA documents reviewed by Reuters on January 15, 2026, highlight tensions between speed and rigorous scrutiny in drug approvals.

Program Background and Goals

The CNPV pilot program selects therapies for expedited, multidisciplinary reviews to tackle U.S. health crises, chronic diseases, and supply vulnerabilities. Vouchers go to drugs advancing innovative cures, affordability, or national security through U.S. production, with 18 awarded so far, including recent batches in October and November 2025. Unlike statutory priority review vouchers, CNPV operates via FDA discretion, promising enhanced communication and rolling reviews for ready applications.

Experts note the initiative’s novelty could modernize approvals but risks compressing essential safety checks. To date, only one generic antibiotic has completed review under the program.

Specific Delays and Safety Flags

FDA postponed Disc Medicine’s bitopertin for erythropoietic protoporphyria (EPP), a rare blood disorder causing severe sunlight sensitivity, from late January to February 10, 2026. Reviewers questioned if trial endpoints like pain-free sunlight time reliably predict benefits and explored misuse potential, despite mid-stage trials showing protoporphyrin IX reductions. Disc CEO John Quisel defended the data’s strength on safety and efficacy, including phototoxic reaction cuts.

Sanofi’s Tzield (teplizumab), already approved to delay Stage 3 type 1 diabetes onset by about two years in at-risk patients, faces a delay over a month for expanded use in advanced cases. Triggers include a treatment-linked fatality, seizures, and blood clotting; FDA sought more adverse event data. Sanofi continues collaborating with regulators.

Other delays: Boehringer Ingelheim’s zongertinib (likely “zertinib” per reports) for HER2-mutated lung cancer to mid-February, and Eli Lilly’s orforglipron, an oral obesity drug yielding significant weight loss in trials, to April 10.

Drug	Company	Condition	Original Target	New Target	Key Concerns
Bitopertin	Disc Medicine	EPP (rare blood disorder)	Late January 2026	Feb 10, 2026	Efficacy endpoints, misuse risk
Tzield (teplizumab)	Sanofi	Advanced type 1 diabetes	Nov 21, 2025	+1 month	Patient death, seizures, clotting
Zongertinib	Boehringer Ingelheim	HER2+ lung cancer	Early 2026	Mid-February 2026	Unspecified extension
Orforglipron	Eli Lilly	Obesity	Q1 2026	April 10, 2026	Timeline extension confirmed

Expert Reactions and Broader Context

Regulatory experts welcomed delays as signs FDA prioritizes science over speed. Holly Fernandez Lynch, University of Pennsylvania health law professor, called it reassuring: “It’s a very good sign the FDA is willing to say, ‘No, this product cannot be allowed on the market'”. Harvard’s Aaron Kesselheim cautioned against vouchers for early-stage drugs, potentially diverting resources.

EPP affects thousands, crippling lives via pain from minimal sun exposure; no disease-modifying treatments exist. Type 1 diabetes impacts 1.6 million Americans, with Stage 3 risking ketoacidosis. Obesity drugs like orforglipron address epidemics, with Phase 3 data showing sustained weight loss versus placebo. Lung cancer, NSCLC dominant, needs targeted options; zongertinib hit 71% response in pretreated HER2 cases.

Public Health Implications

Delays protect patients from unproven risks but slow access to therapies for unmet needs like rare porphyrias or diabetes progression. The program could boost domestic manufacturing and affordability if balanced right, yet politicization fears linger since administration selects candidates. For consumers, it underscores consulting providers before off-label hopes; professionals monitor for post-market data refinements.

Practically, patients with EPP might continue avoiding sunlight, while diabetes families await safer expansions. Success could validate speed for blockbusters, per past voucher sales over $100 million.

Limitations and Counterpoints

Critics argue one-to-two-month reviews inherently rush safety, especially with adverse events like Tzield’s death unelaborated. Companies claim robust data—Disc’s Phase 2 successes, Lilly’s tolerability matching GLP-1 peers. No prior public reporting amplifies transparency issues. Diverse views: boosters see innovation; skeptics, rushed approvals.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.